Clinical Trials in the USA / NCT07135323
Recruiting
Observational
AvertD Post-Approval Study
NCT07135323 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Opioid Use Disorder
Investigational drug(s) / intervention(s)
Opioid Used Disorder Risk Assessment
Opioid Used Disorder Risk Assessment: Determine the likelihood of Opioid Used Disorder prior to prescribing opioids
Study summary
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
Eligibility
Inclusion Criteria:
* ≥18 years of age
* Prior to first opioid prescription
* Being considered for first oral opioid prescription (4-30 days)
* Prescribed AvertD as part of care
* Willing and able to complete yearly assessments for 5 years
* Signed informed consent
Exclusion Criteria:
* Planned opioid prescription \<4 or \>30 days
* Any condition making participation unsafe or infeasible per investigator judgment
Primary outcome measure(s)
- Sensitivity and Specificity of AvertD — Measured over 5 years
Comparison of Averted results to diagnosis of Opioid Used Disorder from M.I.N.I. tool
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Concentrics Research | Indianapolis | Indiana | Recruiting |
Other trials for the same condition
Brain Training for Substance Use Disorders
Recruiting
Remotely Observed Methadone Evaluation II
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07135323 on ClinicalTrials.gov ↗ ← All trials in the USA